SUMMARY
Self-sufficiency (autonomy) in growth signaling, the earliest recognized hallmark of cancer, is fuelled by the tumor cell’s ability to ‘secrete-and-sense’ growth factors; this translates into cell survival and proliferation that is self-sustained by auto-/paracrine secretion. Using breast cancer cells that are either endowed or impaired in growth signaling autonomy, here we reveal how autonomy impacts cancer progression. Autonomy is associated with enhanced molecular programs for stemness, immune evasiveness, proliferation, and epithelial-mesenchymal plasticity (EMP). Autonomy is both necessary and sufficient for anchorage-independent growth factor-restricted proliferation and resistance to anti-cancer drugs and is required for metastatic progression. Transcriptomic and proteomic studies show that autonomy is associated with self-sustained EGFR/ErbB signaling. A gene expression signature is derived (a.k.a., autonomy signature) which revealed that autonomy is induced in circulating tumor cells (CTCs) and particularly CTC clusters, the latter of which carry higher metastatic potential. Autonomy in CTCs tracks therapeutic response and prognosticates outcome. Autonomy is preserved during reversible (but not stable) epithelial-mesenchymal transition (EMT). These data support a role for growth signaling autonomy in multiple processes essential for the blood-borne dissemination of human breast cancer.
In Brief In this work, Sinha et al., reveal a special feature in a subset of circulating tumor cells, i.e., growth signaling autonomy, which makes them better ‘seeds’ for initiating metastases in breast cancer.
HIGHLIGHTS
Autonomy is associated with stemness, immune evasiveness, EM-plasticity, and metastatic potential
Autonomous tumor cells mount a self-sufficient EGFR/ErbB signaling program
Autonomy is induced during reversible (not stable) EMT and requires EGFR/ERBB signaling
Gene signature for autonomy in CTCs tracks therapeutic response and prognosticates outcome
Competing Interest Statement
The authors have declared no competing interest.
